Solas BioVentures led equity financing round for St. Louis-based start-up
Chattanooga’s Solas BioVentures led an equity financing round for InterShunt Technologies Inc., a St. Louis-based early stage medical device company that is developing a novel catheter-based solution to reduce left atrial pressure in heart failure patients. Arsenal Capital Management and a select group of industry executives participated in the funding.
According to this recent news release, the start-up is developing a proprietary catheter system that allows for the capture and excision of tissue from the interatrial septum. The result is a left to right atrial shunt that off-loads elevated left atrial pressure, reducing symptoms in heart failure patients. The mechanical system is designed for safety and ease of use and is the only interatrial shunting device that requires no implant and no energy.
